ClinicalTrials.gg
CompletedNCT04179175Updated Aug 21, 2026Results posted

Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa

A Phase 3 interventional study of secukinumab and secukinumab in Hidradenitis Suppurativa, sponsored by Novartis Pharmaceuticals. Completed at 191 sites in 38 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
702
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies in Hidradenitis Suppurativa by Novartis — 9 open to participants now, 14 under way, 3 of them phase 3. Hidradenitis Suppurativa · Novartis.

Enrollment
2nd of 10
702 · median 545
Started
2020
the only one that year
Phase 3
6 of 21
1 open now
Registered
5th of 21
by date

Among the 21 studies in Hidradenitis Suppurativa by Novartis, this one is the 2nd largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2020, is one of 6 in phase 3, and was the 5th registered.

Hidradenitis Suppurativa

285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

9 of the 21 studies in Hidradenitis Suppurativa by Novartis are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Hidradenitis Suppurativa by Novartis, or all of them as a file.
02

Study summary

The purpose of this extension study is to evaluate maintenance of Hidradenitis Suppurativa Clinical Response (HiSCR response) in either continuous or interrupted therapy (using a randomized withdrawal period) of two dose regimens and to assess long-term efficacy, safety and tolerability of Secukinumab in subjects with moderate to severe hidradenitis suppurativa completing either of the 2 Phase III studies. This is an expanded access trial for the core trials CAIN457M2301 (NCT03713619) and CAIN457M2302 (NCT03713619).

Read the detailed description

This is a multicenter extension study to both core Phase III studies CAIN457M2301 and CAIN457M2302 (Core studies). This study contains a randomized withdrawal design, double blinded and placebo controlled up to Week 104 or loss of response. The subjects with HiSCR response after 52 weeks of treatment in the "Core studies" will be randomized at 2:1 ratio to either continue on one of the two Secukinumab dosing regimens assigned in "Core studies" for another 52 weeks or will be placed on placebo. The primary endpoint is loss of response (LOR) assessed during the 52-week treatment duration (up to Week 104). Subjects who attained LOR will be transferred to open-label treatment to continue until the end of the study. Subjects on placebo who did not reach LOR up to Week 104 will be offered to continue in the open-label treatment or discontinue the study. Thus for subjects who were HiSCR responders at Week 52 of "Core studies", the open label treatment duration will vary and start either from the time of LOR or from Week 104 dose and last until Week 260 followed by 8 weeks of a post treatment follow-up period to week 268.

Subjects who were HiSCR non-responders at the end of "Core studies" will be offered to continue in open-label treatment until Week 260.

Subjects who prematurely discontinue the study, or who complete the study will enter a post-treatment follow up period (8 weeks) The primary objective is to evaluate maintenance of HiSCR response at Week 104 in either continuous or interrupted therapy compared to placebo. Secondary objectives are to assess the long-term safety and tolerability evaluated by adverse events, abnormal laboratory values and vital signs.

03

Conditions studied

  • Hidradenitis Suppurativa

Keywords

  • acne inversa
  • Hidradenitis suppurativa (HS)
  • maladie de Verneuil
  • inflammatory disease
  • AIN457
  • AIN457M
  • Secukinumab
  • Loss of Response (LOR)
  • Hidradenitis Suppurativa Clinical Response (HiSCR)
  • interleukin-17A (IL-17A)
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • written must be obtained before any assessment is performed
  • subject must have completed the study treatment period (52 weeks) in the core studies (AIN457M2301 or AIN457M2302) and had received secukinumab treatment during Treatment Period 2

Exclusion criteria

Exclusion Criteria:

  • protocol deviation in the core study which will prevent the meaningful analysis of the extension study
  • ongoing or planned use of prohibited HS or non-HS treatment
  • participation in the extension could expose the subject to an undue safety risk
  • current sever progressive or uncontrolled disease which renders the subject unsuitable for the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
702 participants (actual)

Study arms

  • Active comparator
    secukinumab 1 HiSCR Responder

    HiSCR responder at Week 52 in core trial, secukinumab 300mg every 2 weeks

    Drug: secukinumab

  • Active comparator
    secukinumab 2 HiSCR Responder

    HiSCR responder at Week 52 in core trial, secukinumab 300mg every 4 weeks

    Drug: secukinumab

  • Placebo comparator
    placebo 1 HiSCR Responder

    HiSCR responder at Week 52 in core trial, placebo to secukinumab 300mg every 2 weeks

    Drug: secukinumab

  • Placebo comparator
    placebo 2 HiSCR Responder

    HiSCR responder at Week 52 in core trial, placebo to secukinumab 300 mg every 4 weeks

    Drug: secukinumab

  • Other
    HiSCR non-responders

    non-responder at Week 52 in core trial treatment; secukinumab 300mg every 2 weeks

    Drug: secukinumab

Interventions

  • secukinumab 300mg every 2 weeks

    Also known as: AIN457

  • secukinumab 300mg every 4 weeks

    Also known as: AIN457

06

What researchers measure

Primary outcomes

  1. Time to Loss of Response (LOR) up to Week 104 in Hidradenitis Suppurativa Clinical Response (HiSCR) Responders

    Loss of response was defined as: * at least a 50% increase in abscess and/or nodules (AN) count compared to the average AN count from the 3 previous visits or at Week 52, whichever is lower and the increase was at least of 3 AN. * at least a 30% increase in AN compared to the average AN count from the 3 previous visits or Week 52, whichever is lower, with an increase of at least 2 AN and a further increase in the AN count of at least 2 AN at a re-assessment visit within 2-4 weeks

    Time frame: Up to 52 weeks: from randomization at the extension study (Week 52) up to Week 104 or loss of response. Study day is defined with respect to the core studies.

  2. Incidence Rate of Participants Achieving Loss of Response (LOR) up to Week 104 in Hidradenitis Suppurativa Clinical Response (HiSCR) Responders

    The incidence rate of participants achieving Loss of Response (LOR) was based on the primary estimand. * Day 1 = Date of 1st dose intake in the extension study. * Subjects at risk = Subjects who did not have LOR and were not censored before or at the start of the specified time interval. * Incidence rate (%) = (number of subjects with LOR / number of subjects at risk) x 100.

    Time frame: Up to 52 weeks: from randomization at the extension study (Week 52) up to Week 104 or loss of response. Study day is defined with respect to the core studies.

Secondary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events

    To assess the long-term safety and tolerability of Secukinumab in subjects with moderate to severe hidradenitis suppurativa (HS)

    Time frame: Up to 216 weeks: from randomization at the extension study (Week 52) up to Week 268. Study day is defined with respect to the core studies.

07

Results

Posted Jun 21, 2024

Participant flow

This study is conducted in 191 centers in 38 countries worldwide

Participant flow — Overall Study
MilestoneAIN457 Q2WR-Q2WAIN457 Q2WR-PBOAIN457 Q4WR-Q4WAIN457 Q4WR-PBOAIN457 Q2WNR-Q2WAIN457 Q4WNR-Q2W
Started1367112163151157
Full analysis set of hiscr responders (fas-r)136711216300
Full analysis set of hiscr non-responders (fas-nr)0000151156
Safety set (saf)1377012163151156
Completed randomized withdrawal period - responders only127641146200
Completed000000
Not completed1367112163151157
Withdrew: Ongoing at the time of the data cut-off date9454954398105
Withdrew: Adverse event533466
Withdrew: Lack of efficacy5132187
Withdrew: Lost to follow-up532245
Withdrew: Physician decision202311
Withdrew: Pregnancy303012
Withdrew: Withdrawal by subject22101282331
Withdrew: Technical problems001100

Outcome measures

PrimaryTime to Loss of Response (LOR) up to Week 104 in Hidradenitis Suppurativa Clinical Response (HiSCR) Responders

Loss of response was defined as: * at least a 50% increase in abscess and/or nodules (AN) count compared to the average AN count from the 3 previous visits or at Week 52, whichever is lower and the increase was at least of 3 AN. * at least a 30% increase in AN compared to the average AN count from the 3 previous visits or Week 52, whichever is lower, with an increase of at least 2 AN and a further increase in the AN count of at least 2 AN at a re-assessment visit within 2-4 weeks

Time frame:
Up to 52 weeks: from randomization at the extension study (Week 52) up to Week 104 or loss of response. Study day is defined with respect to the core studies.
Reported as:
Median · Days
Time to Loss of Response (LOR) up to Week 104 in Hidradenitis Suppurativa Clinical Response (HiSCR) Responders
DaysAIN457 Q2WR-Q2WAIN457 Q2WR-PBOAIN457 Q4WR-Q4WAIN457 Q4WR-PBOAIN457 Q2WNR-Q2WAIN457 Q4WNR-Q2W
Time to Loss of Response (LOR) up to Week 104 in Hidradenitis Suppurativa Clinical Response (HiSCR) Responders283 (176 to —)239 (120 to —)365 (225 to —)171 (113 to 337)——
Statistical analysis
  • AIN457 Q2WR-Q2W vs AIN457 Q2WR-PBO · Log Rank · p = 0.250 · Hazard ratio (hr): 0.87 · 95% CI 0.59 to 1.29one-sided stratified log-rank test, with region and body weight (\<90 kg, ≥ 90 kg) as strata
  • AIN457 Q4WR-Q4W vs AIN457 Q4WR-PBO · Log Rank · p = 0.044 · Hazard ratio (hr): 0.70 · 95% CI 0.47 to 1.05one-sided stratified log-rank test, with region and body weight (\<90 kg, ≥ 90 kg) as strata
SecondaryNumber of Participants With Treatment Emergent Adverse Events

To assess the long-term safety and tolerability of Secukinumab in subjects with moderate to severe hidradenitis suppurativa (HS)

Time frame:
Up to 216 weeks: from randomization at the extension study (Week 52) up to Week 268. Study day is defined with respect to the core studies.

Results for this outcome have not been posted.

PrimaryIncidence Rate of Participants Achieving Loss of Response (LOR) up to Week 104 in Hidradenitis Suppurativa Clinical Response (HiSCR) Responders

The incidence rate of participants achieving Loss of Response (LOR) was based on the primary estimand. * Day 1 = Date of 1st dose intake in the extension study. * Subjects at risk = Subjects who did not have LOR and were not censored before or at the start of the specified time interval. * Incidence rate (%) = (number of subjects with LOR / number of subjects at risk) x 100.

Time frame:
Up to 52 weeks: from randomization at the extension study (Week 52) up to Week 104 or loss of response. Study day is defined with respect to the core studies.
Reported as:
Number · Percentage of participants
Incidence Rate of Participants Achieving Loss of Response (LOR) up to Week 104 in Hidradenitis Suppurativa Clinical Response (HiSCR) Responders
Percentage of participantsAIN457 Q2WR-Q2WAIN457 Q2WR-PBOAIN457 Q4WR-Q4WAIN457 Q4WR-PBOAIN457 Q2WNR-Q2WAIN457 Q4WNR-Q2W
Day 10.00.00.00.0——
2 to 85 days26.923.924.230.2——
86 to 141 days12.421.212.425.6——
142 to 197 days8.49.86.69.4——
198 to 253 days8.18.110.113.8——
254 to 309 days10.418.26.54.0——
310 to 351 days3.30.01.84.2——
352 to 399 days5.40.05.49.1——

Adverse events

Collected over From first dose of study treatment in the extension (Week 52) up to the cut-off date for the interim analysis (26-May-2023), approximately 3 years. Study day is defined with respect to the core studies.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AIN457 Q2WR-Q2W0/137 (0%)2/137 (1.5%)44/137 (32.1%)
AIN457 Q2WR-PBO0/70 (0%)4/70 (5.7%)23/70 (32.9%)
AIN457 Q4WR-Q4W0/121 (0%)5/121 (4.1%)46/121 (38%)
AIN457 Q4WR-PBO0/63 (0%)5/63 (7.9%)16/63 (25.4%)
Any AIN457 Q4W0/180 (0%)11/180 (6.1%)71/180 (39.4%)
Any AIN457 Q2W0/637 (0%)72/637 (11.3%)379/637 (59.5%)
Any AIN4570/687 (0%)80/687 (11.6%)428/687 (62.3%)
AIN457 NR0/307 (0%)37/307 (12.1%)199/307 (64.8%)
Most frequent serious events
Showing 10 of 85
Most frequent serious events
EventAIN457 Q2WR-Q2WAIN457 Q2WR-PBOAIN457 Q4WR-Q4WAIN457 Q4WR-PBOAny AIN457 Q4WAny AIN457 Q2WAny AIN457AIN457 NR
HidradenitisSkin and subcutaneous tissue disorders1/1370/701/1210/631/18023/63723/68714/307
Tongue coatedGastrointestinal disorders0/1370/700/1211/630/1800/6370/6870/307
DiverticulitisInfections and infestations0/1370/700/1211/630/1800/6370/6870/307
Oesophageal candidiasisInfections and infestations0/1370/700/1211/630/1800/6370/6870/307
Labia enlargedReproductive system and breast disorders0/1370/700/1211/630/1800/6370/6870/307
Perineal indurationReproductive system and breast disorders0/1370/700/1211/630/1800/6370/6870/307
Skin ulcerSkin and subcutaneous tissue disorders0/1370/700/1211/630/1800/6370/6870/307
COVID-19Infections and infestations0/1371/700/1210/630/1802/6372/6871/307
GastroenteritisInfections and infestations0/1371/700/1210/630/1801/6371/6871/307
Groin abscessInfections and infestations0/1371/700/1210/630/1800/6370/6870/307
Most frequent other events
Showing 10 of 42
Most frequent other events
EventAIN457 Q2WR-Q2WAIN457 Q2WR-PBOAIN457 Q4WR-Q4WAIN457 Q4WR-PBOAny AIN457 Q4WAny AIN457 Q2WAny AIN457AIN457 NR
COVID-19Infections and infestations11/1376/7011/1217/6319/180128/637147/68758/307
HidradenitisSkin and subcutaneous tissue disorders6/1374/704/1213/636/18070/63775/68745/307
NasopharyngitisInfections and infestations5/1372/706/1212/638/18055/63763/68732/307
HeadacheNervous system disorders3/1370/704/1210/639/18032/63741/68715/307
EczemaSkin and subcutaneous tissue disorders3/1374/703/1211/634/18022/63726/68713/307
C-reactive protein increasedInvestigations1/1370/700/1210/632/18020/63722/68715/307
Upper respiratory tract infectionInfections and infestations1/1370/703/1211/635/18028/63733/68714/307
BronchitisInfections and infestations2/1370/700/1212/631/18028/63729/68714/307
CoughRespiratory, thoracic and mediastinal disorders0/1370/703/1210/633/18020/63723/68714/307
AcneSkin and subcutaneous tissue disorders0/1371/702/1210/632/18020/63722/68714/307

Baseline characteristics

Age, Continuous
Age, Continuous(Years)AIN457 Q2WR-Q2WAIN457 Q2WR-PBOAIN457 Q4WR-Q4WAIN457 Q4WR-PBOAIN457 Q2WNR-Q2WAIN457 Q4WNR-Q2WTotal
Mean35.7 ± 11.2634.8 ± 10.5535.4 ± 12.5936.0 ± 11.3237.3 ± 11.0037.1 ± 11.1336.1 ± 11.31
Sex: Female, Male
Sex: Female, Male(Participants)AIN457 Q2WR-Q2WAIN457 Q2WR-PBOAIN457 Q4WR-Q4WAIN457 Q4WR-PBOAIN457 Q2WNR-Q2WAIN457 Q4WNR-Q2WTotal
Female733864289178372
Male633357356079327
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)AIN457 Q2WR-Q2WAIN457 Q2WR-PBOAIN457 Q4WR-Q4WAIN457 Q4WR-PBOAIN457 Q2WNR-Q2WAIN457 Q4WNR-Q2WTotal
White113519048115111528
Black or African American8611761452
Asian1211136242894
Native Hawaiian or Other Pacific Islander0000101
American Indian or Alaska Native22523317
Multiple1120217
08

Study locations

191 sites
  • Northwest Arkansas Center
    Rogers, Arkansas 72758, United States
  • MedDerm Associates
    San Diego, California 92103, United States
  • University Clinical Trials
    San Diego, California 92123, United States
  • Southern California Skin and Laser
    Whittier, California 92677, United States
  • Florida Academic Centers Research and Education LLC
    Coral Gables, Florida 33134, United States
  • University of MiamiHealth System
    Miami, Florida 33125, United States
  • Olympian Clinical Research
    Tampa, Florida 33609, United States
  • University Of South Florida
    Tampa, Florida 33612, United States
  • Advanced Medical Research
    Sandy Springs, Georgia 30328, United States
  • Endeavor Health
    Glenview, Illinois 60077, United States
  • Dundee Dermatology
    West Dundee, Illinois 60118, United States
  • Dawes Fretzin Clinical Rea Group
    Indianapolis, Indiana 46256, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Beth Israel Deaconess Med Center
    Boston, Massachusetts 02215, United States
  • Minnesota Clinical Study Center
    New Brighton, Minnesota 55112, United States
  • MediSearch Clinical Trials
    Saint Joseph, Missouri 64506, United States
  • St Louis U Clinical Trials
    St Louis, Missouri 63104, United States
  • WA Uni School Of Med
    St Louis, Missouri 63110, United States
  • Skin Specialists PC
    Omaha, Nebraska 68144, United States
  • Icahn School Of Med At Mount Sinai
    New York, New York 10029, United States
  • University of North Carolina
    Chapel Hill, North Carolina 27516, United States
  • Wright State University
    Fairborn, Ohio 45324, United States
  • UP Medical Center H System
    Pittsburgh, Pennsylvania 15213-3403, United States
  • Clinical Research Ctr of Carolinas
    Charleston, South Carolina 29407, United States
  • Bellaire Dermatology Associates
    Bellaire, Texas 77401, United States
  • MDRI Baylor University
    Dallas, Texas 75246-1613, United States
  • Austin Inst for Clinical Research
    Pflugerville, Texas 78660, United States
  • Dr. Stephen Miller, MDPA
    San Antonio, Texas 78229, United States
  • Virginia Clinical Research
    Norfolk, Virginia 23507, United States
  • Novartis Investigative Site
    Buenos Aires, Buenos Aires C1425DKG, Argentina
  • Novartis Investigative Site
    CABA, Buenos Aires C1056ABI, Argentina
  • Novartis Investigative Site
    La Plata, Buenos Aires B1902COS, Argentina
  • Novartis Investigative Site
    Rosario, Santa Fe Province 2000, Argentina
  • Novartis Investigative Site
    Caba, C1425BEA, Argentina
  • Novartis Investigative Site
    Capital Federal, C1023AAB, Argentina
  • Novartis Investigative Site
    Phillip, Australian Capital Territory 2606, Australia
  • Novartis Investigative Site
    Benowa, Queensland 4217, Australia
  • Novartis Investigative Site
    East Melbourne, Victoria 3002, Australia
  • Novartis Investigative Site
    Linz, 4020, Austria
  • Novartis Investigative Site
    Vienna, 1090, Austria
  • Novartis Investigative Site
    Brussels, Brussels Capital 1070, Belgium
  • Novartis Investigative Site
    Ghent, 9000, Belgium
  • Novartis Investigative Site
    Liège, 4000, Belgium
  • Novartis Investigative Site
    Sofia, Bulgaria 1407, Bulgaria
  • Novartis Investigative Site
    Stara Zagora, Bulgaria 6000, Bulgaria
  • Novartis Investigative Site
    Pleven, 5800, Bulgaria
  • Novartis Investigative Site
    Sofia, 1606, Bulgaria
  • Novartis Investigative Site
    Barrie, Ontario L4M 7G1, Canada
  • Novartis Investigative Site
    London, Ontario N6H 5L5, Canada
  • Novartis Investigative Site
    Peterborough, Ontario K9J 5K2, Canada
  • Novartis Investigative Site
    Waterloo, Ontario N2J 1C4, Canada
  • Novartis Investigative Site
    Barranquilla, Atlántico 080002, Colombia
  • Novartis Investigative Site
    Zagreb, HRV 10000, Croatia
  • Novartis Investigative Site
    Prague, Prague 1 11000, Czechia
  • Novartis Investigative Site
    Jihlava, 586 01, Czechia
  • Novartis Investigative Site
    Plzen Bory, 301 00, Czechia
  • Novartis Investigative Site
    Ústí nad Labem, 400 11, Czechia
  • Novartis Investigative Site
    Limoges, Haute Vienne 87000, France
  • Novartis Investigative Site
    Toulon, Val De Marne 83800, France
  • Novartis Investigative Site
    Antony, 92160, France
  • Novartis Investigative Site
    Bordeaux, 33075, France
  • Novartis Investigative Site
    Brest, 29609, France
  • Novartis Investigative Site
    Créteil, 94010, France
  • Novartis Investigative Site
    Lyon, 69003, France
  • Novartis Investigative Site
    Martigues, 13500, France
  • Novartis Investigative Site
    Montpellier, 34295, France
  • Novartis Investigative Site
    Nantes, 44093, France
  • Novartis Investigative Site
    Nice, 06202, France
  • Novartis Investigative Site
    Paris, 75475, France
  • Novartis Investigative Site
    Reims, 51100, France
  • Novartis Investigative Site
    Rouen, 76031, France
  • Novartis Investigative Site
    Saint-Mandé, 94160, France
  • Novartis Investigative Site
    Saint-Priest-en-Jarez, 42270, France
  • Novartis Investigative Site
    Toulouse, 31400, France
  • Novartis Investigative Site
    Langenau, Baden-Wurttemberg 89129, Germany
  • Novartis Investigative Site
    Munich, Bavaria 81377, Germany
  • Novartis Investigative Site
    Würzburg, Bavaria 97080, Germany
  • Novartis Investigative Site
    Frankfurt, Germany 60590, Germany
  • Novartis Investigative Site
    Halle, Saxony-Anhalt 06108, Germany
  • Novartis Investigative Site
    Berlin, 10789, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Bielefeld, 33647, Germany
  • Novartis Investigative Site
    Bochum, 44791, Germany
  • Novartis Investigative Site
    Erlangen, 91054, Germany
  • Novartis Investigative Site
    Hamburg, 20246, Germany
  • Novartis Investigative Site
    Heidelberg, 69120, Germany
  • Novartis Investigative Site
    Memmingen, 87700, Germany
  • Novartis Investigative Site
    München, 80377, Germany
  • Novartis Investigative Site
    Münster, 48149, Germany
  • Novartis Investigative Site
    Potsdam, 14467, Germany
  • Novartis Investigative Site
    Schwerin, 19055, Germany
  • Novartis Investigative Site
    Athens, 161 21, Greece
  • Novartis Investigative Site
    Chaïdári, 124 62, Greece
  • Novartis Investigative Site
    Thessaloniki, 546 43, Greece
  • Novartis Investigative Site
    Thessaloniki, 564 03, Greece
  • Novartis Investigative Site
    Guatemala City, Departamento de Guatemala 01010, Guatemala
  • Novartis Investigative Site
    Guatemala City, 1015, Guatemala
  • Novartis Investigative Site
    Pécs, Baranya 7623, Hungary
  • Novartis Investigative Site
    Debrecen, Hajdu Bihar Megye 4032, Hungary
  • Novartis Investigative Site
    Kaposvár, 7400, Hungary

Showing the first 100 of 191 sites across 38 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Kimball AB, Bechara FG, Badat A, Giamarellos-Bourboulis EJ, Gottlieb AB, Jemec GBE, Reguiai Z, Villani AP, Alarcon I, Bansal A, Gasperoni F, Martin R, Paguet B, Uhlmann L, Zouater H, Ravichandran S, Alavi A. Long-term efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: week 104 results from the SUNSHINE and SUNRISE extension trial. Br J Dermatol. 2025 Mar 18;192(4):629-640. doi: 10.1093/bjd/ljae469. PubMed 39611771 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2020 to primary completion in May 2023, 38 months.

Results were first posted in Jun 2024, 1 year after primary completion.

Of 26 phase 3 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 38. This study's 38 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2019
First posted
Nov 27, 2019
StartActual
Mar 18, 2020
Primary completionActual
May 26, 2023
CompletionActual
Jul 15, 2026
Results first posted
Jun 21, 2024
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04179175
Responsible party
Sponsor
First posted
Nov 27, 2019
Start date
Mar 18, 2020
Primary completion
May 26, 2023
Completion
Jul 15, 2026
Results posted
Jun 21, 2024
Last update
Aug 21, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion